[ORGANIZATION]
Ozempic
Featured in 4 tracked stories · first seen
Situations
Novo Nordisk obesity portfolio: EU approval, legal fight
93 clusters · 431 sources · last updated
Latest: US Medicare Launches GLP-1 Bridge Program to Cut Drug Costs
Novo Nordisk’s obesity portfolio keeps expanding. The European Commission confirmed marketing authorisation for the once‑daily 25 mg oral semaglutide (Wegovy) tablet, the first oral GLP‑1 approved for weight management i
GLP‑1 weight‑loss drug scrutiny
2 clusters · 6 sources · last updated
Latest: Ozempic weight‑loss drug fuels health concerns and K‑pop idol debate
In late July 2026, attention turned to the scientific validity of emerging weight‑loss products. An initial report highlighted the hype around personalized nutrition services and a bitter‑hop supplement marketed as a nat
US food industry concentration and health policy
2 clusters · 6 sources · last updated
Latest: Food Industry Confronts Legal Battles and US Market Shift Amid Health Initiatives
A small group of multinational food corporations dominate the U.S. market, using loosely regulated terms such as “natural” and “healthy” to label products—a practice described as health‑washing. This concentration raises
GLP‑1 market, usage & emerging safety signals
175 clusters · 628 sources · last updated
Latest: GLP-1 weight‑loss drugs linked to hair loss and higher divorce rates
GLP‑1 receptor agonists have become mainstream weight‑loss treatments, now used in primary‑care, tele‑health and covered by Medicare‑CMS, with market value projected near $105 billion by 2030. Observational BMJ data on ≈